1/27/2024 0 Comments Blueprint medicinesThe words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidates, including the results of ongoing clinical trials the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients and Blueprint Medicines' financial performance, growth strategy, goals and anticipated milestones, business plans and focus. For more information, visit follow us on Twitter and LinkedIn.Ĭautionary Note Regarding Forward-Looking Statements Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. ET)īlueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Session Date & Time: Monday, Jfrom 11:30 a.m. Session Title: Rapid Abstract Session: Lung Cancer Short Oral Presentation Title: BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study Session Date & Time: Sunday, Jfrom 8:00 a.m. Session Title: Lung Cancer-Non-Small Cell Metastatic Poster Presentation Title: Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions Session Date & Time: Saturday, Jfrom 8:00 a.m. Session Title: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology Poster Presentation Title: BLU-222, an oral, potent and selective CDK2 inhibitor, in patients with advanced solid tumors: phase 1 monotherapy dose escalation The accepted abstracts are listed below, and abstract titles are available today on the ASCO conference website:. "Collectively, the datasets represent another step toward achieving our 2027 Blueprint for Precision at Scale – our five-year growth strategy to reach broad patient populations through the development of transformative precision therapies." "These upcoming presentations reflect important clinical progress toward realizing the promise of our innovative precision therapies to help address complex medical needs in lung and breast cancer, leveraging our scientific and development expertise with the goal of overcoming traditional limitations of targeted therapy," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. Results from the ongoing dose escalation part of the CONCERTO trial of BLU-451 in EGFR exon 20 insertion-positive NSCLC showing early safety and clinical activity.Updated results from the dose escalation part of the SYMPHONY trial showing the safety and tolerability of BLU-945 as a monotherapy and in combination with osimertinib in patients with late-line, EGFR-mutant non-small cell lung cancer (NSCLC).Results from the ongoing dose escalation part of the VELA trial of BLU-222 in breast cancer and other cancers vulnerable to CDK2 inhibition, showing evidence of monotherapy safety and pathway modulation. The datasets to be reported at the ASCO Annual Meeting include:
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |